Please assess the completion status of the following clinical trial:

Trial Title: Acid Lipase Replacement Investigating Safety and Efficacy (ARISE) in Participants With Lysosomal Acid Lipase Deficiency

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participant and/or participant's parent or legal guardian provided informed consent.~* Participant was ≥ 4 years of age on the date of informed consent.~* Deficiency of LAL enzyme activity confirmed by dried blood spot testing at screening.~* Alanine aminotransferase ≥ 1.5x upper limit of normal on 2 consecutive screening measurements obtained at least 1 week apart.~* Female participants of childbearing potential must not have been pregnant or breastfeeding and must have agreed to use a medically acceptable method of preventing contraception from screening until 4 weeks after the last dose of study drug.~* Participant receiving lipid-lowering therapies must have been on a stable dose of the medication for at least 6 weeks prior to randomization and was willing to remain on a stable dose for at least the first 32 weeks of treatment in the study.~* Participant receiving medications for the treatment of nonalcoholic fatty liver disease must have been on a stable dose for at least 16 weeks prior to randomization and was willing to remain on a stable dose for at least the first 32 weeks of treatment in the study.~Exclusion Criteria:~* Severe hepatic dysfunction (Child-Pugh Class C).~* Other medical conditions or comorbidities, which, in the opinion of the Investigator, would have interfered with study compliance or data interpretation.~* Previous hematopoietic or liver transplant procedure.~* Received treatment with high-dose corticosteroids (acute or chronic) within 26 weeks. (Note: Participants receiving maintenance therapy with low-dose oral, intranasal, topical, or inhaled corticosteroids were considered eligible for the study).~* Known hypersensitivity to eggs.~* Participated in a study employing an investigational medicinal product within 4 weeks prior to randomization.

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Double-blind Sebelipase Alfa (Type: EXPERIMENTAL): Double-blind Period: IV infusions of sebelipase alfa at a dose of 1 mg/kg administered qow for 20 weeks.
- Double-blind Placebo (Type: PLACEBO_COMPARATOR): Double-blind Period: IV infusions of matched placebo administered qow for 20 weeks.
- Open-label Sebelipase Alfa/Sebelipase Alfa (Type: EXPERIMENTAL): Participants who were randomized to receive sebelipase alfa during the Double-blind Period and received sebelipase alfa in the Open-label Period. All participants received sebelipase alfa at a dose of 1 mg/kg qow, irrespective of treatment received in the Double-blind Period. Dose modifications were permitted during the Open-label Period.
- Open-label Placebo/Sebelipase Alfa (Type: EXPERIMENTAL): Participants who were randomized to receive placebo during the Double-blind Period and received sebelipase alfa in the Open-label Period. All participants received sebelipase alfa at a dose of 1 mg/kg qow, irrespective of treatment received in the Double-blind Period. Dose modifications were permitted during the Open-label Period.

Based on this trial design, predict the completion outcome and termination type (if applicable).